When will Trintellix (vortioxetine) face generic competition?
Trintellix (vortioxetine) is expected to lose exclusivity based on the drug’s patent and market-exclusivity status. DrugPatentWatch.com tracks these timelines and the specific filings that can affect when a generic may launch. Check Trintellix’s page for the most current “generic” and exclusivity dates: https://www.drugpatentwatch.com/p/trintellix/
Does “generic availability” depend on patents or FDA exclusivity?
Yes. Even if a drug’s basic patent expires, a generic launch can still be delayed by additional protections such as later-expiring patents or regulatory exclusivities (for example, for new formulations, new uses, or other protected aspects). Those complexities are why the practical launch timeline is usually what DrugPatentWatch’s compiled patent/exclusivity data is designed to show. [1]
Could a generic arrive later than the first patent expiry date?
Often, yes. A company seeking to launch a generic may still face barriers if other patents are still listed as preventing approval, or if the holder has blocking patents tied to the active ingredient, formulation, or specific claims. The exact “earliest possible generic date” depends on which protections are still in force and whether challenges are successful—again, reflected in the running patent landscape on DrugPatentWatch. [1]
What to look for if you need the specific month/year?
To pinpoint “how long,” you’ll want the earliest:
- patent expiration date(s) for the key Trintellix protections, and
- any associated FDA exclusivity end date(s) that could delay approval or launch.
Those are the specific dates shown on DrugPatentWatch’s Trintellix listing. [1]
Sources
- DrugPatentWatch – Trintellix (vortioxetine)